Immunosurveillance and Immunotherapy of Tumors by Innate Immune Cells

Overview

Journal Curr Opin Immunol

Publisher Elsevier

Specialty Allergy & Immunology

Date 2015 Dec 22

PMID 26686774

Citations 51

Authors

Alexandre Iannello

Thornton W Thompson

Michele Ardolino

Assaf Marcus

David H Raulet

Affiliations

Soon will be listed here.

Abstract

Increasing evidence supports a role for innate immune effector cells in tumor surveillance. Natural killer (NK) cells and myeloid cells represent the two main subsets of innate immune cells possessing efficient but quite different tumor suppressive abilities. Here, we describe the germline-encoded NK cell receptors that play a role in suppressing tumor development and describe briefly the cellular pathways leading to the upregulation of their ligands in tumor cells. We also describe mechanisms underlying the elimination of tumor cells by macrophages and a recently characterized mechanism dedicated to sensing cytosolic DNA that is implicated in antitumor immune responses.

Citing Articles

High Level of CD8PD-1 Cells in Patients with Chronic Myeloid Leukemia Who Experienced Loss of MMR after Imatinib Discontinuation.

Kwasnik P, Zaleska J, Link-Lenczowska D, Zawada M, Wysoglad H, Ochrem B Cells. 2024; 13(8.

PMID: 38667336 PMC: 11048908. DOI: 10.3390/cells13080723.

Hypoxia mediates immune escape of pancreatic cancer cells by affecting miR-1275/AXIN2 in natural killer cells.

Ou Z, Lu Y, Xu D, Luo Z Front Immunol. 2023; 14:1271603.

PMID: 38035113 PMC: 10684956. DOI: 10.3389/fimmu.2023.1271603.

Tumor microenvironment-responsive DNA-based nanomedicine triggers innate sensing for enhanced immunotherapy.

Li J, Han X, Gao S, Yan Y, Li X, Wang H J Nanobiotechnology. 2023; 21(1):382.

PMID: 37858171 PMC: 10585899. DOI: 10.1186/s12951-023-02132-6.

Inhibition of IL-12 heterodimers impairs TLR9-mediated prevention of early mouse plasmacytoma cell growth.

Mandour M, Soe P, Castonguay A, Van Snick J, Coutelier J Front Med (Lausanne). 2023; 9:1057252.

PMID: 36714124 PMC: 9880182. DOI: 10.3389/fmed.2022.1057252.

The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited.

Dzobo K, Senthebane D, Dandara C Cancers (Basel). 2023; 15(2).

PMID: 36672326 PMC: 9856874. DOI: 10.3390/cancers15020376.

References

Textor S, Fiegler N, Arnold A, Porgador A, Hofmann T, Cerwenka A . Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res. 2011; 71(18):5998-6009. DOI: 10.1158/0008-5472.CAN-10-3211. View

Norman J, Mashiba M, McNamara L, Onafuwa-Nuga A, Chiari-Fort E, Shen W . The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells. Nat Immunol. 2011; 12(10):975-83. PMC: 3530928. DOI: 10.1038/ni.2087. View

Tokuyama M, Lorin C, Delebecque F, Jung H, Raulet D, Coscoy L . Expression of the RAE-1 family of stimulatory NK-cell ligands requires activation of the PI3K pathway during viral infection and transformation. PLoS Pathog. 2011; 7(9):e1002265. PMC: 3178570. DOI: 10.1371/journal.ppat.1002265. View

Kaifu T, Escaliere B, Gastinel L, Vivier E, Baratin M . B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cell Mol Life Sci. 2011; 68(21):3531-9. PMC: 11114815. DOI: 10.1007/s00018-011-0802-7. View

Li H, Lakshmikanth T, Garofalo C, Enge M, Spinnler C, Anichini A . Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. Cell Cycle. 2011; 10(19):3346-58. DOI: 10.4161/cc.10.19.17630. View

Chao M, Majeti R, Weissman I . Programmed cell removal: a new obstacle in the road to developing cancer. Nat Rev Cancer. 2011; 12(1):58-67. DOI: 10.1038/nrc3171. View

Lin D, Lavender H, Soilleux E, OCallaghan C . NF-κB regulates MICA gene transcription in endothelial cell through a genetically inhibitable control site. J Biol Chem. 2011; 287(6):4299-310. PMC: 3281736. DOI: 10.1074/jbc.M111.282152. View

Glasner A, Ghadially H, Gur C, Stanietsky N, Tsukerman P, Enk J . Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1. J Immunol. 2012; 188(6):2509-15. DOI: 10.4049/jimmunol.1102461. View

Willingham S, Volkmer J, Gentles A, Sahoo D, Dalerba P, Mitra S . The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012; 109(17):6662-7. PMC: 3340046. DOI: 10.1073/pnas.1121623109. View

10.

Cerwenka A, Bakker A, McClanahan T, Wagner J, Wu J, Phillips J . Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity. 2000; 12(6):721-7. DOI: 10.1016/s1074-7613(00)80222-8. View

11.

Diefenbach A, Jamieson A, Liu S, Shastri N, Raulet D . Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol. 2001; 1(2):119-26. DOI: 10.1038/77793. View

12.

Diefenbach A, Jensen E, Jamieson A, Raulet D . Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001; 413(6852):165-71. PMC: 3900321. DOI: 10.1038/35093109. View

13.

Cerwenka A, Baron J, Lanier L . Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A. 2001; 98(20):11521-6. PMC: 58762. DOI: 10.1073/pnas.201238598. View

14.

Garrido F, Algarra I . MHC antigens and tumor escape from immune surveillance. Adv Cancer Res. 2001; 83:117-58. DOI: 10.1016/s0065-230x(01)83005-0. View

15.

Groh V, Wu J, Yee C, Spies T . Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002; 419(6908):734-8. DOI: 10.1038/nature01112. View

16.

Diefenbach A, Hsia J, Hsiung M, Raulet D . A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Eur J Immunol. 2003; 33(2):381-91. DOI: 10.1002/immu.200310012. View

17.

Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B . Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003; 198(4):557-67. PMC: 2194180. DOI: 10.1084/jem.20030788. View

18.

Raulet D . Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003; 3(10):781-90. DOI: 10.1038/nri1199. View

19.

Tahara-Hanaoka S, Shibuya K, Onoda Y, Zhang H, Yamazaki S, Miyamoto A . Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int Immunol. 2004; 16(4):533-8. DOI: 10.1093/intimm/dxh059. View

20.

Molinero L, Fuertes M, Girart M, Fainboim L, Rabinovich G, Costas M . NF-kappa B regulates expression of the MHC class I-related chain A gene in activated T lymphocytes. J Immunol. 2004; 173(9):5583-90. DOI: 10.4049/jimmunol.173.9.5583. View